CA2146973C - Utilisations d'un fragment du recepteur du tgf-.beta. a des fins therapeutiques - Google Patents
Utilisations d'un fragment du recepteur du tgf-.beta. a des fins therapeutiques Download PDFInfo
- Publication number
- CA2146973C CA2146973C CA002146973A CA2146973A CA2146973C CA 2146973 C CA2146973 C CA 2146973C CA 002146973 A CA002146973 A CA 002146973A CA 2146973 A CA2146973 A CA 2146973A CA 2146973 C CA2146973 C CA 2146973C
- Authority
- CA
- Canada
- Prior art keywords
- tgf
- beta
- fragment
- rii
- excess
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96837592A | 1992-10-29 | 1992-10-29 | |
US07/968,375 | 1992-10-29 | ||
US3759793A | 1993-03-26 | 1993-03-26 | |
US08/037,597 | 1993-03-26 | ||
PCT/US1993/010455 WO1994009815A1 (fr) | 1992-10-29 | 1993-10-29 | UTILISATIONS D'UN FRAGMENT DE RECEPTEUR DU TGF-β COMME AGENT THERAPEUTIQUE |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2146973A1 CA2146973A1 (fr) | 1994-05-11 |
CA2146973C true CA2146973C (fr) | 2008-09-02 |
Family
ID=26714287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002146973A Expired - Fee Related CA2146973C (fr) | 1992-10-29 | 1993-10-29 | Utilisations d'un fragment du recepteur du tgf-.beta. a des fins therapeutiques |
Country Status (8)
Country | Link |
---|---|
US (1) | US5693607A (fr) |
EP (1) | EP0669833B1 (fr) |
JP (1) | JPH08504763A (fr) |
AU (1) | AU669256B2 (fr) |
CA (1) | CA2146973C (fr) |
DE (1) | DE69332026T2 (fr) |
ES (1) | ES2174868T3 (fr) |
WO (1) | WO1994009815A1 (fr) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US7384634B2 (en) | 1991-08-30 | 2008-06-10 | University Of South Florida | Connective tissue growth factor |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
AU671606B2 (en) * | 1991-10-31 | 1996-09-05 | Whitehead Institute For Biomedical Research | TGF-beta type receptor cDNAs and uses therefor |
US6395494B1 (en) | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
AU688409B2 (en) * | 1993-11-19 | 1998-03-12 | University Of Sydney, The | A method for preventing or controlling cataract |
EP0735895B1 (fr) * | 1993-11-19 | 2006-01-18 | The University Of Sydney | Procede de prevention ou de reduction de la cataracte |
US5866323A (en) * | 1995-04-07 | 1999-02-02 | Case Western Reserve University | Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors |
GB2304045A (en) * | 1995-08-04 | 1997-03-12 | Univ Manchester | Betaglycan compositions for promoting the healing of wounds and fibrotic diseases |
WO1998046588A2 (fr) * | 1997-04-11 | 1998-10-22 | Neorx Corporation | Composes et therapies destines a la prevention d'affections vasculaires ou non vasculaires |
DK0975771T3 (da) * | 1997-04-18 | 2007-10-22 | Biogen Idec Inc | Fusionsproteiner af TGF-beta-receptortype II og immunoglobulins konstante region |
ZA988461B (en) | 1997-09-18 | 1999-03-30 | Idec Pharma Corp | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
JP2001206899A (ja) * | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | TGF−βII型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
US6534693B2 (en) * | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
US20040241211A9 (en) * | 2000-11-06 | 2004-12-02 | Fischell Robert E. | Devices and methods for reducing scar tissue formation |
US20030180301A1 (en) * | 2002-01-22 | 2003-09-25 | Shaf Keshavjee | Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection |
ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
US7795389B2 (en) * | 2004-09-28 | 2010-09-14 | The Board Of Regents Of The University Of Texas System | Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins |
EP1809324A4 (fr) * | 2004-10-13 | 2009-02-25 | Univ Ohio State Res Found | Methodes de traitement ou de prevention de troubles lymphoproliferatifs associes à des virus |
US8597646B2 (en) | 2005-10-25 | 2013-12-03 | The Johns Hopkins University | Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders |
EP1998810A4 (fr) | 2006-03-13 | 2009-09-02 | Univ Johns Hopkins | Augmentation de la thromborésistance endothéliale |
EP2083863B1 (fr) | 2006-10-03 | 2015-03-18 | Genzyme Corporation | Anticorps contre le tgf-beta pour l'utilisation dans le traitement des nourrissons risquant de développer une dysplasie broncho-pulmonaire |
EP2171062A1 (fr) * | 2007-06-15 | 2010-04-07 | Genzyme Corporation | Protéines de fusion contenant deux domaines de liaison tgf-bêta du récepteur tgf-bêta de type ii |
US8946201B2 (en) * | 2007-08-27 | 2015-02-03 | Saint Louis University | Methods for inhibiting TGF-β |
EP2341913B1 (fr) * | 2008-09-16 | 2014-11-19 | Saint Louis University | Procédé d'amélioration de signalisation tgf-bêta |
TR201816180T4 (tr) | 2010-03-12 | 2018-11-21 | Genzyme Corp | Meme kanserini tedavi etmek için kombinasyonlu tedavi. |
WO2012090997A1 (fr) | 2010-12-27 | 2012-07-05 | 京都府公立大学法人 | CELLULES SPi ET LEUR PROCÉDÉ DE PRODUCTION |
EP2737083A1 (fr) | 2011-07-27 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Scientifique) | Méthodes de diagnostic et de traitement du syndrome de myhre |
AU2011379972B2 (en) | 2011-10-26 | 2016-05-12 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
WO2013100208A1 (fr) | 2011-12-28 | 2013-07-04 | 京都府公立大学法人 | Normalisation d'une culture de cellules endothéliales de la cornée |
CN105658672A (zh) | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
JPWO2015064768A1 (ja) | 2013-10-31 | 2017-03-09 | 京都府公立大学法人 | 角膜内皮の小胞体細胞死関連疾患治療薬 |
AR098827A1 (es) | 2013-12-19 | 2016-06-15 | Consejo Nac De Investig Científicas Y Técnicas (Conicet) | ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS |
WO2016187312A1 (fr) | 2015-05-18 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Procédés et compositions pour traiter une infection par alphavirus |
AU2016301380B2 (en) | 2015-08-04 | 2021-07-01 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
IL305536A (en) | 2017-03-02 | 2023-10-01 | Nat Res Council Canada | TGF–B receptor ectodomain fusion compounds and their uses |
SI3628049T1 (sl) | 2017-05-04 | 2023-10-30 | Acceleron Pharma Inc. | Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba |
UA128306C2 (uk) | 2017-05-12 | 2024-06-05 | Джянгсу Хенгруй Медісін Ко., Лтд. | ЗЛИТІ ПРОТЕЇНИ, ЯКІ МІСТЯТЬ РЕЦЕПТОР TGF-<font face="Symbol">b</font>, І ЇХ ФАРМАЦЕВТИЧНЕ ЗАСТОСУВАННЯ |
CN112119157A (zh) | 2018-03-06 | 2020-12-22 | 宾夕法尼亚大学董事会 | 前列腺特异性膜抗原car及其使用方法 |
KR20200130403A (ko) | 2018-03-09 | 2020-11-18 | 아게누스 인코포레이티드 | 항-cd73 항체 및 그의 사용 방법 |
BR112020025804A2 (pt) | 2018-06-22 | 2021-03-23 | Kite Pharma, Inc. | proteínas transmembranares quiméricas e usos das mesmas |
US20220017601A1 (en) | 2018-11-09 | 2022-01-20 | Jiangsu Hengrui Medicine Co., Ltd. | TGF-beta RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF |
JP2022527972A (ja) | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前悪性病変を有する患者において癌を予測及び予防する方法 |
CN113968903A (zh) | 2020-07-24 | 2022-01-25 | 迈威(上海)生物科技股份有限公司 | TGF-β RII突变体及其融合蛋白 |
WO2023141724A1 (fr) | 2022-01-28 | 2023-08-03 | 35Pharma Inc. | Variants de type iib du récepteur de l'activine et leurs utilisations |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4886747A (en) * | 1985-03-22 | 1989-12-12 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
JP2612874B2 (ja) * | 1986-10-02 | 1997-05-21 | マサチユセツツ・インスチチユート・オブ・テクノロジー | タンパク質の代謝的安定性を調節する方法 |
US5084384A (en) * | 1987-04-23 | 1992-01-28 | Monsanto Company | Secretion of insulin-like growth factor-I |
US5108919A (en) * | 1988-06-24 | 1992-04-28 | Genentech, Inc. | Dna sequences encoding yeast ubiquitin hydrolase |
CA2002011A1 (fr) * | 1988-11-14 | 1990-05-14 | Anthony F. Purchio | Recepteur de tgf-beta regulateur de la croissance humaine normale |
EP0413440B1 (fr) * | 1989-07-19 | 1995-08-09 | Tonen Corporation | Peptidyl prolyl-cis, trans-isomérase |
ZA914750B (en) * | 1990-06-20 | 1992-03-25 | Bristol Myers Squibb Co | Methods of modulating blood pressure using tgf-beta and antagonists thereof |
US5187151A (en) * | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
AU671606B2 (en) * | 1991-10-31 | 1996-09-05 | Whitehead Institute For Biomedical Research | TGF-beta type receptor cDNAs and uses therefor |
WO1993010215A1 (fr) * | 1991-11-15 | 1993-05-27 | Memorial Sloan-Kettering Cancer Center | Proteaglicane betaglycane purifiee, compositions et procedes |
MX9301135A (es) * | 1992-03-06 | 1993-09-01 | Steven G Reed | Metodo para tratar infecciones por patogeno de macrofago. |
WO1994018991A1 (fr) * | 1993-02-19 | 1994-09-01 | Celtrix Pharmaceuticals, Inc. | Expansion de cellules souches dans les cultures sur une longue duree de m×lle osseuse par neutralisation du facteur de croissance transformant beta |
EP0637450A3 (fr) * | 1993-08-04 | 1995-04-05 | Collagen Corp | Méthode et composition pour revigorer le tissu cicatriciel. |
AU8016894A (en) * | 1993-10-15 | 1995-05-04 | La Jolla Cancer Research Foundation | Betaglycan polypeptides having tgf-beta binding activity |
-
1993
- 1993-10-29 AU AU56650/94A patent/AU669256B2/en not_active Ceased
- 1993-10-29 JP JP6511364A patent/JPH08504763A/ja not_active Ceased
- 1993-10-29 CA CA002146973A patent/CA2146973C/fr not_active Expired - Fee Related
- 1993-10-29 WO PCT/US1993/010455 patent/WO1994009815A1/fr active IP Right Grant
- 1993-10-29 EP EP94902198A patent/EP0669833B1/fr not_active Expired - Lifetime
- 1993-10-29 ES ES94902198T patent/ES2174868T3/es not_active Expired - Lifetime
- 1993-10-29 DE DE69332026T patent/DE69332026T2/de not_active Expired - Lifetime
-
1994
- 1994-12-22 US US08/361,873 patent/US5693607A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5693607A (en) | 1997-12-02 |
ES2174868T3 (es) | 2002-11-16 |
DE69332026T2 (de) | 2002-10-31 |
JPH08504763A (ja) | 1996-05-21 |
WO1994009815A1 (fr) | 1994-05-11 |
EP0669833A1 (fr) | 1995-09-06 |
AU669256B2 (en) | 1996-05-30 |
DE69332026D1 (de) | 2002-07-18 |
CA2146973A1 (fr) | 1994-05-11 |
AU5665094A (en) | 1994-05-24 |
EP0669833A4 (fr) | 1996-07-31 |
EP0669833B1 (fr) | 2002-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2146973C (fr) | Utilisations d'un fragment du recepteur du tgf-.beta. a des fins therapeutiques | |
AU696764B2 (en) | Vascular endothelial growth factor 2 | |
JP4044140B2 (ja) | インスリン誘導体類とその使用 | |
JP4854851B2 (ja) | 改善された生物活性と生体適合性のためのタンパク質の部位特異的二重ポリエチレングリコール化 | |
EP0559769B1 (fr) | Mitogene de liaison d'heparine presentant une homologie avec le facteur de croissance epidermique (egf) | |
JP3854307B2 (ja) | 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害 | |
EP0977583B1 (fr) | Compositions comprenant des conjugues de proteine ob humaine, active, stable avec une chaine fc d'immunoglobulins et leurs procedes | |
US6521227B1 (en) | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides | |
WO2018032787A1 (fr) | Protéine de fusion d'hormone de croissance humaine hautement glycosylée, son procédé de fabrication et son application | |
US6638912B2 (en) | Peptide compositions mimicking TGF-β activity | |
EP3431507B1 (fr) | Protéine de fusion comprenant un facteur de croissance nerveuse et procédé de préparation et utilisation correspondants | |
PT94754B (pt) | Processo de obtencao de inibidor de factor de necrose tumoral e de isolamento de genes que codificam o referido inibidor | |
JP2003525864A (ja) | 共有結合で架橋されたインスリンダイマー | |
JPH07500315A (ja) | 骨成長因子の標的送達 | |
KR20010006534A (ko) | Ⅱ형 tgf-베타 수용체/면역글로불린 불변 영역 융합 단백질 | |
JP2001526239A (ja) | 角質細胞増殖因子−2製剤 | |
JP2002526073A (ja) | 新規のヒト生長分化因子のコード配列、そのdna配列によりコードされるポリペプチド、およびこれらの製造方法。 | |
EP1320541A2 (fr) | Inhibiteurs de tgf-beta et methodes associees | |
AU2001253920A1 (en) | Use of taci as an anti-tumor agent | |
WO2001081417A2 (fr) | Taci utilisee en tant qu'agent antitumoral | |
US7282351B2 (en) | Prostatic growth factor | |
JP2019513724A (ja) | コンジュゲートされたc1エステラーゼインヒビター及びその使用 | |
CZ389397A3 (cs) | Stimulační faktor kostí | |
JP2000505643A (ja) | レクチン様性質を有する化合物およびその生物学的応用 | |
US6235884B1 (en) | Heparin binding mitogen with homology to epidermal growth factor (EGF) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |